Get started
Author

Mark Rolfe

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
2009 · Teresa A. Soucy, Peter G. Smith, et al. · Nature · 1,979
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
1995 · Michele Pagano, Sun W. Tam, et al. · Science · 1,817
A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B
1995 · Randall W King, Jan-Michael Peters, et al. · Cell · 956
PDF
Drug discovery in the ubiquitin–proteasome system
2006 · Grzegorz Nalepa, Mark Rolfe, et al. · Nature Reviews Drug Discovery · 611
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2010 · Erik Kupperman, Edmund C. Lee, et al. · Cancer Research · 500
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
2010 · James E. Brownell, Michael D. Sintchak, et al. · Molecular Cell · 465
PDF
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis
2015 · Daniel J. Anderson, Ronan Le Moigne, et al. · Cancer Cell · 391
PDF
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
2018 · Mary E. Matyskiela, Suzana Couto, et al. · Nature Chemical Biology · 329
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
2010 · Michael A. Milhollen, Tary Traore, et al. · Blood · 323
PDF
Targeted Therapies for Cancer 2004
2004 · Jeffrey S. Ross, David P. Schenkein, et al. · American Journal of Clinical Pathology · 286
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells
2020 · Christine Surka, Liqing Jin, et al. · Blood · 224
PDF
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
2009 · Teresa A. Soucy, Peter G. Smith, et al. · Clinical Cancer Research · 220
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
2015 · Han-Jie Zhou, Jinhai Wang, et al. · Journal of Medicinal Chemistry · 195
Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
2006 · Josep Domingo-Domenech, Cristina Oliva, et al. · Clinical Cancer Research · 166
Reconstitution of p53-ubiquitinylation reactions from purified components: the role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP).
1995 · M Rolfe, P Beer-Romero, et al. · Proceedings of the National Academy of Sciences · 115
Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells
1997 · Peggy Beer-Romero, Susan Glass, et al. · Oncogene · 113
The ubiquitin-mediated proteolytic pathway as a therapeutic area
1997 · Mark Rolfe, M. Isabel Chiu, et al. · Journal of Molecular Medicine · 112
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
2017 · Ronan Le Moigne, Blake T. Aftab, et al. · Molecular Cancer Therapeutics · 111
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors
2002 · Zhihong Lai, Tao Yang, et al. · Proceedings of the National Academy of Sciences · 106
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
2006 · Jordi Codony-Servat, Maria A. Tapia, et al. · Molecular Cancer Therapeutics · 104
PDF
Crystal structure of the SALL4–pomalidomide–cereblon–DDB1 complex
2020 · Mary E. Matyskiela, Thomas Clayton, et al. · Nature Structural & Molecular Biology · 100
CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity
2019 · Victoria A. Assimon, Yangzhong Tang, et al. · ACS Chemical Biology · 97
UBE2G1 governs the destruction of cereblon neomorphic substrates
2018 · Gang Lu, Stephanie Weng, et al. · eLife · 78
Human SPF45, a Splicing Factor, Has Limited Expression in Normal Tissues, Is Overexpressed in Many Tumors, and Can Confer a Multidrug-Resistant Phenotype to Cells
2003 · Janardhan Sampath, Pandy R. Long, et al. · American Journal Of Pathology · 77
PDF
The JAMM motif of human deubiquitinase Poh1 is essential for cell viability
2007 · Melissa Gallery, Jonathan L. Blank, et al. · Molecular Cancer Therapeutics · 74
Works count: 121
Citation count: 10,300
H-index: 34
I10-index: 45
Year
Topic
Type